Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence

Video

In this video, David A. Ginsberg, MD, discusses the takeaways of the study, “Long-term, repeat treatments with onabotulinumtoxinA are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Eiftu S. Haile, MD, answers a question during a Zoom video interview
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
DNA strands | Image Credit: ©  Matthieu - stock.adobe.com
Doctor consulting with patient | Image Credit: © Khunatorn - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.